MyoKardia, Inc. Common Stock
MYOK
MYOK was delisted on the 16th of November, 2020.
168 hedge funds and large institutions have $2.41B invested in MyoKardia, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 68 increasing their positions, 35 reducing their positions, and 18 closing their positions.
128% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 18
94% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 35
37% more call options, than puts
Call options by funds: $5.53M | Put options by funds: $4.04M
36% more capital invested
Capital invested by funds: $1.77B → $2.41B (+$631M)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
16% more funds holding
Funds holding: 145 → 168 (+23)
Top Buyers
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$46.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$41.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.4M |
| 4 |
HM
HealthCor Management
New York
|
+$33.7M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$32.3M |
Top Sellers
MYOK Hedge Fund Activity: Q1 2019 in Review
168 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in MyoKardia, Inc. Common Stock (MYOK) for Q1 2019, worth a combined $2.41B — up 36% from $1.77B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new MYOK positions and 18 closed out — a net gain of 23 holders — while 68 added to existing stakes and 35 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $46.1M. The largest seller was Federated Hermes, cutting an estimated $16.8M.
- 168 institutional investors held MyoKardia, Inc. Common Stock (MYOK) as of Q1 2019, up from 145 in Q4 2018.
- Funds reported $2.41B of MyoKardia, Inc. Common Stock stock for Q1 2019, up 36% quarter-over-quarter.
- 41 funds opened new MyoKardia, Inc. Common Stock positions in Q1 2019 and 18 closed out, a net change of +23 holders.
- The largest MyoKardia, Inc. Common Stock buyer in Q1 2019 was Avoro Capital Advisors, an estimated $46.1M added.
- The largest MyoKardia, Inc. Common Stock seller in Q1 2019 was Federated Hermes, an estimated $16.8M sold.
Based on aggregated 13F filings for Q1 2019.